 By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Testing DN-TNF Platform as Treatment for COVID-19 On April 20, 2020, INmune Bio, Inc. NASDAQ:INMB announced that the company will be testing the companys dominant-negative tumor necrosis factor DN-TNF platform as a treatment for COVID-19 caused by the novel coronavirus SARS-CoV-2. The DN-TNF platform is based 